Early Access Programmes for Pharmaceuticals in Europe
-
The EMA's PRIME (PRIority MEdicines) scheme is the latest attempt to accelerate access for innovative drugs to the European market. This seminar addresses not only this programme, but also provides you with a thorough understanding of the various programmes and methods currently facilitating pharmaceuticals' market access.50.9451256 6.9617125
| Wann |
17.02.2016 von 09:00 bis 17:00 |
|---|---|
| Veranstaltungsort | Köln Marriott Hotel |
| Stadt | Köln |
| Kontaktname | Dr. Henriette Wolf-Klein |
| Kontakttelefon | 06221 500-680 |
| Zielgruppe |
This seminar addresses the needs of pharmaceutical industry employees who work in medical affairs, market access or healthcare management. Especially those dealing with market access strategies within Europe will benefit from this course. |
| Termin übernehmen |
vCal
iCal
|
Aims and objectives
The EMA's PRIME (PRIority MEdicines) scheme is the latest attempt to accelerate access for innovative drugs to the European market. This seminar addresses not only this programme, but also provides you with a thorough understanding of the various programmes and methods currently facilitating pharmaceuticals' market access.
After attending this seminar, you will have a core set of ideas on how to speed up market access for your products and know for exactly which programmes your product is eligible.
Topics
- Conditional approval
- Compassionate use and off-label use
- Named patient programme and expanded access programme
- French ATU - Best practice?
- Early access for orphans
- EMA's PRIME scheme
Weitere Informationen über diesen Termin…
FORUM Institut für Management GmbH
Programm
1602236.pdf
—
PDF document,
275 kB (281,709 bytes)
